Routine meeting notice with no immediate price catalyst. The key items (EIB warrant restructuring and equity recapitalization) were already priced via the June 2 424B5 offering. Monitor shareholder vote outcomes on June 30 and subsequent updates on the NATiV3 trial for lanifibranor.
Price Chart
Executive Summary
Inventiva S.A. filed a notice for its Ordinary and Extraordinary General Meeting on June 30, 2026, with 40 resolutions covering approval of 2025 financials, director appointments, capital increase delegations, share buyback authorization, and notably, Resolution 36 acknowledging shareholders' equity is less than half the share capital (no dissolution, continue operations) and Resolution 39 authorizing the issuance of 15,677,573 warrants to the EIB as part of a previously announced refinancing and warrant restructuring. This 6-K is a procedural meeting notice; all material items (EIB refinancing, dilutive offering) were disclosed in prior filings.
Key Facts
- General Meeting scheduled for June 30, 2026 at Hotel Villa M, Paris.
- Resolution 36 acknowledges shareholders' equity is less than half the share capital – company resolves not to dissolve early and to continue operations.
- Resolution 39 authorizes issuance of 15,677,573 warrants to the European Investment Bank at EUR 0.01 each, exercisable at EUR 0.01 per share, as part of restructuring existing EIB loan and 2022 EIB warrants.
- Routine items include approval of 2025 annual financial statements showing net loss of EUR 207,965,630.56, director renewals, capital increase delegations up to EUR 2,000,000 nominal, and share buyback authorization up to 10% of capital.
Financial Impact
No new financial figures; previously disclosed net loss of EUR 207,965,630.56 for FY2025 and $120M ADS offering completed June 5, 2026.
Risk Factors
- Shareholders' equity below half of share capital increases risk of mandatory dissolution if not restored within two fiscal years.
- Potential dilution from exercise of 15.7M EIB warrants and ongoing capital raise authorizations.
- Pre-revenue biotech with significant cash burn and reliance on trial results.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-073144 |
| Document: tm2617723d1_6k.htm | 0001104659-26-073144 |
| Document: 0001104659-26-073144-index-headers.html | 0001104659-26-073144 |
| Document: 0001104659-26-073144-index.html | 0001104659-26-073144 |
| Document: 0001104659-26-073144.txt | 0001104659-26-073144 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | — | awaiting T+20 | — | — |
Oct 6, 2026 21d ago | 6-K | $3.37 | awaiting T+20 | — | $3.68 (+9.51%) |
Sep 28, 2026 29d ago | 6-K | $3.53 $3.66 | ▲ +3.68% | ▲ +3.71% | $3.68 (+4.39%) |
Sep 3, 2026 7w ago | 6-K | $4.84 $3.56 | ▼ −26.45% | ▼ −25.26% | $3.68 (−23.86%) |
Jul 6, 2026 16w ago | 6-K | $3.90 $4.48 | ▲ +14.87% | ▲ +15.44% | $3.68 (−5.51%) |
Jun 12, 2026 19w ago | 6-K | $3.76 $4.30 | ▲ +14.36% | ▲ +15.11% | $3.68 (−1.99%) |
Jun 12, 2026 19w ago | 6-K | $3.85 $4.30 | ▲ +11.69% | ▲ +9.91% | $3.68 (−4.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers